Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Wolverine peptide stack (BPC-157 and TB-500): what is in it and does it work?

The Wolverine stack pairs BPC-157 and TB-500 for injury recovery. No study has tested the pair, and HHS's draft peptide policy does not cover blends.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

At a glance

The Wolverine stack is a nickname for BPC-157 and TB-500 used together, sold premixed or as two vials, for injury recovery. No study has tested the pair. BPC-157 rests mainly on animal data, and TB-500 has no human study: the trials often cited for it used full-length thymosin beta-4, a different substance. HHS's October 28, 2026 draft enforcement policy covers BPC-157 and TB-500 only as separate single-ingredient compounded products, so a mix of the two is not covered and has no lawful path.

Evidence: Blend never studiedRegulatory: No federal basis to compoundWADA: WADA prohibited
What is in it
BPC-157, TB-500
Evidence for the combination
No published study of the blend. Each ingredient is graded on its own.
Legal status
No federal basis to compound, set by BPC-157 and TB-500.
Tested athletes
Prohibited: BPC-157 and TB-500 are on the WADA list.

What is in the Wolverine stack?

Wolverine stack contains BPC-157 and TB-500. The name refers to the pair, not a fixed product. It is sold as a premixed vial, as two separate vials, and as oral capsules, with amounts and ratios that vary by seller. TB-500 is a 7 amino acid fragment of thymosin beta-4, but whether a given product sold as TB-500 contains the fragment or the full-length peptide is not verified. PeptideAgent does not name or link sellers.

Also searched as: Wolverine peptide; Wolverine peptide stack; BPC-157 and TB-500; BPC-157 TB-500 blend; BPC 157 and TB 500.

Ingredients in the Wolverine stack, with each peptide's own evidence grade, FDA status, and WADA status
IngredientWhy it is in the mixStatus (alone)
BPC-157Sold for tendon, ligament, muscle, and gut healing, based on rodent studies.
Evidence: Animal-only evidence
Regulatory: HHS interim policy (draft)
WADA: WADA prohibited
TB-500Sold for wound repair, flexibility, and recovery, based on animal studies of full-length thymosin beta-4, a different substance from TB-500.
Evidence: Animal-only evidence
Regulatory: HHS interim policy (draft)
WADA: WADA prohibited

Grades and statuses come from each peptide's own record and update with it. Grades follow the methodology.

Why are these peptides combined in the Wolverine stack?

The name borrows a comic-book character who heals fast. The logic offered is that the two peptides work on repair by different routes: BPC-157 is said to promote blood vessel growth and tendon cell outgrowth, and thymosin beta-4 binds actin and drives cell migration into wounds. TB-500 is a synthetic 7 amino acid fragment of thymosin beta-4, which FDA says is not the same substance, and it is hypothesized, not shown, to share that role.

Both mechanisms come from animal and cell studies. In rats, BPC-157 improved tendon healing, cell survival, and cell migration, and full-length thymosin beta-4 sped full thickness wound closure. FDA identified no animal study testing whether TB-500 itself promotes wound healing. Whether the two effects add up, overlap, or interfere has never been measured. [1] [2] [3] [14]

Has the Wolverine stack been studied?

No published study has tested BPC-157 and TB-500 together in humans or animals, and PubMed indexes no trial of the combination.

Alone, neither has much human data. A 2025 systematic review of BPC-157 in orthopaedic sports medicine included 36 studies, 35 of them preclinical; the one clinical report was a retrospective series in which 7 of 12 people with knee pain reported relief after an injection into the joint. It found no clinical safety data. Across the wider literature, BPC-157 has three small uncontrolled pilot reports (knee pain, interstitial cystitis, IV safety), with no control group. No human study of TB-500 itself has been identified. The small phase 1 and phase 2 human trials often cited for it (IV safety, eye drops for dry eye, a topical form for skin ulcers) tested full-length thymosin beta-4, which FDA says is not the same substance as TB-500.

The evidence grade of the stack therefore cannot be higher than that of its ingredients, and both are graded on animal data. [4] [5] [11] [12] [13] [14]

What each ingredient has shown alone

  • BPC-157 (animal-only evidence). A 15 amino acid peptide with strong animal healing data, no randomized human trial in PubMed, and a draft HHS compounding policy from October 2026.
  • TB-500 (animal-only evidence). Synthetic 7 amino acid fragment of thymosin beta-4. No human study of TB-500 itself; the human trials used the full-length protein. WADA banned.

Wolverine stack results and before and after claims

Before and after stories for the Wolverine stack usually describe a faster return from a tendon, joint, or muscle injury. Injuries often improve with time, rest, and rehabilitation, so recovery after starting a product does not show the product caused it.

The only human data for either peptide are BPC-157's three small uncontrolled pilot reports (knee pain, interstitial cystitis, IV safety). TB-500 has no human study: the small phase 1 and phase 2 trials often cited for it (IV safety, eye drops for dry eye, a topical form for skin ulcers) tested full-length thymosin beta-4, which FDA says is not the same substance. No study has measured healing time, strength, or pain after injected BPC-157 and TB-500 together.

A 2026 review of peptide use in sports medicine highlights the placebo effect, and its amplification on social media, as an explanation for many reported results. [4] [5] [6] [11] [12] [13] [14]

What are the side effects of the Wolverine stack?

There is no safety study of the combination. A systematic review found no clinical safety data for BPC-157, and there are no systematic human safety data for injected TB-500.

Reported problems are injection site reactions, headache, lethargy, nausea, and dizziness, mostly anecdotal. BPC-157 and thymosin beta-4, the protein TB-500 is a fragment of, promote blood vessel growth or cell migration in animals, which raises a theoretical concern about existing tumors that has not been tested in people.

Unregulated products add contamination and content uncertainty, a risk the BPC-157 systematic review names directly. Both peptides are prohibited for athletes subject to anti-doping testing. [3] [5] [6] [10]

Reported for each ingredient

From each peptide's record. These were reported for the peptide alone, not for the blend. Absence of data is not evidence of safety.

Side effects reported for each ingredient of the Wolverine stack
IngredientReported side effects and safety notes
BPC-157
  • No systematic human safety data; three small uncontrolled pilot reports (about 30 people in total) reported no adverse events
  • Injection site reactions reported anecdotally
  • Nausea and dizziness reported anecdotally
  • Theoretical concern about promoting growth of existing tumors because it stimulates angiogenesis through VEGFR2 in animal and cell studies (not demonstrated in humans)
TB-500
  • No human safety data for TB-500: FDA found no report of it being given to humans and no animal toxicity studies
  • FDA concern: compounded TB-500 may pose a risk of immune reactions (immunogenicity) for certain routes because of aggregation and peptide related impurities
  • Full-length thymosin beta-4 (a different substance), two phase 1 intravenous studies in healthy volunteers: mild to moderate adverse events, no serious adverse events or dose limiting toxicity
  • Full-length thymosin beta-4 eye drop trial: no adverse events observed over 28 days
Regulatory: No federal basis to compoundWADA: WADA prohibited

A blend inherits the strictest status among its ingredients, because a mixed product is only as lawful as its least lawful component. For the Wolverine stack that is BPC-157 and TB-500: no federal basis to compound. At least one ingredient is not FDA approved and not on the 503A bulks list, so a licensed pharmacy has no federal basis to compound the mix.

Why blends like this are sold as research chemicals

A drug for human use in the United States has to be FDA approved or lawfully compounded by a licensed pharmacy for a named patient under a prescription. This blend can be neither, so vials sold under its name carry labels such as “for research use only” or “not for human consumption”. That label does not make a product lawful to inject, and it means no one has checked the vial for identity, purity, sterility, or amount. [7]

WADA status

BPC-157 and TB-500 are prohibited at all times on the WADA list, so any product containing them is prohibited for athletes subject to anti-doping testing.

State rules: peptide laws by state. All FDA actions: regulatory tracker.

What does the Wolverine stack cost, and what can a provider lawfully offer?

A Wolverine stack is not covered by HHS's new draft policy. On October 28, 2026, HHS released a draft enforcement discretion policy saying it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds BPC-157 or TB-500 under strict conditions, but only as a single-ingredient product. Blends and stacks, including a premixed BPC-157 and TB-500 vial, are not covered. The policy is a draft, not an FDA approval, does not add either peptide to the 503A bulks list, and is not binding. The notice was published in the Federal Register on October 30, 2026, and comments are open through November 13, 2026.

For each peptide alone, the draft policy requires a patient-specific prescription, an allowed route (BPC-157: subcutaneous, intramuscular, oral, or topical; TB-500: subcutaneous or intramuscular), bulk substance from an FDA-registered manufacturer with a tested certificate of analysis, and reporting of serious adverse events to FDA. Both nominations were moved to FDA's withdrawn list in April 2026. At the July 2026 Pharmacy Compounding Advisory Committee meeting, FDA's drug center recommended against listing each peptide and the committee voted in favor, according to Appendix B of the HHS policy. State law still applies.

Clinic and research-chemical prices are not a lawful price. Research-chemical products are labeled not for human use and are not verified for identity or purity. [7] [8] [9] [16] [17]

What's actually offered, and what that means for you

Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [18] [19] [20]

Being offered does not change the legal status of the Wolverine stack. BPC-157 and TB-500 are not FDA approved and not on the 503A bulks list, so a pharmacy has no federal basis to compound the mix. [7] [21]

Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [9] [18] [21] [22] [23] [24]

What that means for you

  • A pharmacy that compounds the Wolverine stack is taking a regulatory risk: it has no federal basis to do so, and FDA has sent warning letters to compounders for the same thing. [18] [22]
  • No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [9]
  • State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [25]
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [26] [27]
  • Identity, purity, sterility, and dose accuracy can vary from batch to batch. [21]
  • Insurance rarely covers it, so you usually pay cash.
  • For tested athletes, the Wolverine stack contains at least one ingredient that is prohibited under the WADA Prohibited List. [10]

If you're going ahead anyway

These steps lower some risks. They do not make the product safe, and they do not give a pharmacy a federal basis to compound the Wolverine stack, with or without a prescription. [7]

Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [28] [29] [30]

What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [20] [30] [31]

Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [9] [32] [33] [34] [35] [36]

Check for:

  • A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [9]
  • A real evaluation by a licensed prescriber, not just an online form.
  • A certificate of analysis for the specific batch.

Questions to ask

  • Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [28]
  • Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [20]
  • Pharmacy: Is this made for me on a prescription written in my name? [31]
  • Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [20] [30]
  • Prescriber: What is the legal basis for a pharmacy to compound the Wolverine stack? Is it FDA approved or on the 503A bulks list? [7] [9]
  • Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [20]

In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [25]

Compare the ingredients

Blends that share an ingredient

  • GLOW: GLOW is a gray-market mix of GHK-Cu, BPC-157, and TB-500 sold for skin and healing. No study has tested it, and HHS's draft peptide policy excludes blends.
  • KLOW: KLOW is GLOW plus KPV: GHK-Cu, BPC-157, TB-500, and KPV in one vial. No study has tested it, and HHS's draft policy excludes blends.

Frequently asked questions

What is the Wolverine stack?

It is a nickname for BPC-157 and TB-500 used together for injury recovery, sold premixed or as two vials. BPC-157 has mostly animal evidence, TB-500 has no human study, and the pair has never been tested. [3] [5] [14]

Does the Wolverine stack work?

There is no evidence either way for the pair. BPC-157 has rodent healing studies and three small uncontrolled pilot reports (knee pain, interstitial cystitis, IV safety). No human study of TB-500 itself has been identified. The small phase 1 and phase 2 human trials often cited for it (IV safety, eye drops for dry eye, a topical form for skin ulcers) tested full-length thymosin beta-4, which FDA says is not the same substance as TB-500. [4] [11] [12] [13] [14]

Is BPC-157 with TB-500 better than either alone?

No one has tested that. Without a study of the pair, any claim of synergy is a hypothesis built on separate animal studies. [5] [6]

Is the Wolverine stack legal?

No. HHS's October 28, 2026 draft enforcement policy covers BPC-157 and TB-500 only as separate single-ingredient compounded products, so a premixed stack is not covered. Neither peptide is FDA approved or on the 503A bulks list, and research-chemical products sold for human use are unapproved drugs. [7] [15] [17]

What are the side effects of the Wolverine stack?

No study has recorded them. Injection site reactions, headache, lethargy, nausea, and dizziness are reported anecdotally, and neither injected peptide has clinical safety data. [3] [5]

Is the Wolverine stack allowed for tested athletes?

No. BPC-157 is prohibited at all times under WADA section S0 and TB-500 under section S2. [10]

What is the difference between BPC-157 and TB-500?

BPC-157 is a 15 amino acid fragment of a protein found in gastric juice. TB-500 is a synthetic 7 amino acid fragment of thymosin beta-4, an actin binding protein present in nearly all human cells, and FDA says TB-500 and thymosin beta-4 are not the same substance. The comparison page sets out their evidence side by side. [2] [3] [14]

From the blog

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

  1. [1]Malinda KM et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol 1999PubMed 10469335, 1999
  2. [2]The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration (J Appl Physiol 2011)PubMed 21030672, 2011
  3. [3]Goldstein AL et al. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther 2012PubMed 22074294, 2012
  4. [4]Sosne G et al. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, phase II clinical trial. Clin Ophthalmol 2015PubMed 26056426, 2015
  5. [5]Vasireddi N et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J 2025PubMed 40756949, 2025
  6. [6]Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med 2026PubMed 41966639, 2026
  7. [7]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
  8. [8]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
  9. [9]FDA: Compounding and the FDA, questions and answers (including risks of compounded drugs and enforcement policy for nominated bulk substances)FDA, 2026
  10. [10]WADA Prohibited List (section S0 non-approved substances; section S2 peptide hormones, growth factors, related substances and mimetics)WADA

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, October 28). Wolverine peptide stack (BPC-157 and TB-500): what is in it and does it work?. https://peptideagent.ai/blends/wolverine-stack
HTML link
<a href="https://peptideagent.ai/blends/wolverine-stack">Wolverine peptide stack (BPC-157 and TB-500): what is in it and does it work?</a>, PeptideAgent, updated October 28, 2026.